Amgen (NASDAQ:AMGN) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.
Other research analysts also recently issued research reports about the company. Leerink Swann reiterated a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Atlantic Securities downgraded Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective on the stock. in a report on Monday, February 5th. Oppenheimer set a $205.00 price objective on Amgen and gave the company a “buy” rating in a report on Friday, January 5th. Credit Suisse Group increased their price objective on Amgen from $191.00 to $194.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Finally, Mizuho upped their target price on Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, February 12th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $191.26.
AMGN stock opened at $169.43 on Friday. Amgen has a 1-year low of $152.16 and a 1-year high of $201.23. The company has a market capitalization of $130,846.88, a PE ratio of 65.93, a PEG ratio of 2.23 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter in the previous year, the company posted $2.89 EPS. The company’s revenue was down 2.7% compared to the same quarter last year. sell-side analysts forecast that Amgen will post 13.25 earnings per share for the current year.
Amgen announced that its board has authorized a share repurchase program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 4,575 shares of company stock valued at $838,064 over the last ninety days. 0.19% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Sterling Investment Advisors Ltd. raised its stake in shares of Amgen by 1.7% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 12,749 shares of the medical research company’s stock worth $2,196,000 after buying an additional 215 shares in the last quarter. Calamos Wealth Management LLC raised its stake in shares of Amgen by 583.9% during the 2nd quarter. Calamos Wealth Management LLC now owns 9,411 shares of the medical research company’s stock worth $1,621,000 after buying an additional 8,035 shares in the last quarter. Calamos Advisors LLC raised its stake in shares of Amgen by 152.7% during the 2nd quarter. Calamos Advisors LLC now owns 229,811 shares of the medical research company’s stock worth $39,580,000 after buying an additional 138,852 shares in the last quarter. Ffcm LLC raised its stake in shares of Amgen by 6.4% during the 2nd quarter. Ffcm LLC now owns 23,698 shares of the medical research company’s stock worth $4,082,000 after buying an additional 1,428 shares in the last quarter. Finally, Manchester Capital Management LLC raised its stake in shares of Amgen by 2.5% during the 2nd quarter. Manchester Capital Management LLC now owns 5,316 shares of the medical research company’s stock worth $916,000 after buying an additional 130 shares in the last quarter. 79.50% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Amgen (AMGN) Cut to Sell at BidaskClub” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/24/amgen-amgn-cut-to-sell-at-bidaskclub.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.